BACKGROUND: Anemia is a common complication of chronic kidney disease (CKD) that negatively impacts the quality of life and is associated with numerous adverse outcomes. Excess levels of the iron regulatory hormone hepcidin are thought to contribute to anemia in CKD patients by decreasing iron availability from the diet and from body stores. Adenine treatment in rats has been proposed as an animal model of anemia of CKD with high hepcidin levels that mirrors the condition in human patients. METHODS: We developed a modified adenine-induced kidney disease model with a higher survival rate than previously reported models, while maintaining persistent kidney disease and anemia. We then tested whether the small molecule bone morphogenetic protein (BMP) inhibitor LDN-193189, which was previously shown to lower hepcidin levels in rodents, mobilized iron into the plasma and improved iron-restricted erythropoiesis in this model. RESULTS: Adenine-treated rats exhibited increased hepatic hepcidin mRNA, decreased serum iron, increased spleen iron content, low hemoglobin (Hb) and inappropriately low erythropoietin (EPO) levels relative to the degree of anemia. LDN-193189 administration to adenine-treated rats lowered hepatic hepcidin mRNA, mobilized stored iron into plasma and increased Hb content of reticulocytes. CONCLUSIONS: Our data suggest that hepcidin lowering agents may provide a new therapeutic strategy to improve iron availability for erythropoiesis in CKD.
BACKGROUND:Anemia is a common complication of chronic kidney disease (CKD) that negatively impacts the quality of life and is associated with numerous adverse outcomes. Excess levels of the iron regulatory hormone hepcidin are thought to contribute to anemia in CKDpatients by decreasing iron availability from the diet and from body stores. Adenine treatment in rats has been proposed as an animal model of anemia of CKD with high hepcidin levels that mirrors the condition in humanpatients. METHODS: We developed a modified adenine-induced kidney disease model with a higher survival rate than previously reported models, while maintaining persistent kidney disease and anemia. We then tested whether the small molecule bone morphogenetic protein (BMP) inhibitor LDN-193189, which was previously shown to lower hepcidin levels in rodents, mobilized iron into the plasma and improved iron-restricted erythropoiesis in this model. RESULTS:Adenine-treated rats exhibited increased hepatic hepcidin mRNA, decreased serum iron, increased spleen iron content, low hemoglobin (Hb) and inappropriately low erythropoietin (EPO) levels relative to the degree of anemia. LDN-193189 administration to adenine-treated rats lowered hepatic hepcidin mRNA, mobilized stored iron into plasma and increased Hb content of reticulocytes. CONCLUSIONS: Our data suggest that hepcidin lowering agents may provide a new therapeutic strategy to improve iron availability for erythropoiesis in CKD.
Entities:
Keywords:
anemia; chronic kidney disease; hepcidin; iron; mouse model
Authors: Igor Theurl; Andrea Schroll; Thomas Sonnweber; Manfred Nairz; Milan Theurl; Wolfgang Willenbacher; Kathrin Eller; Dominik Wolf; Markus Seifert; Chia Chi Sun; Jodie L Babitt; Charles C Hong; Tracey Menhall; Patrick Gearing; Herbert Y Lin; Guenter Weiss Journal: Blood Date: 2011-07-05 Impact factor: 22.113
Authors: Andrea U Steinbicker; Chetana Sachidanandan; Ashley J Vonner; Rushdia Z Yusuf; Donna Y Deng; Carol S Lai; Kristen M Rauwerdink; Julia C Winn; Borja Saez; Colleen M Cook; Brian A Szekely; Cindy N Roy; Jasbir S Seehra; Gregory D Cuny; David T Scadden; Randall T Peterson; Kenneth D Bloch; Paul B Yu Journal: Blood Date: 2011-03-10 Impact factor: 22.113
Authors: Claire Mayeur; Starsha A Kolodziej; Amy Wang; Xin Xu; Arthur Lee; Paul B Yu; John Shen; Kenneth D Bloch; Donald B Bloch Journal: Haematologica Date: 2014-10-17 Impact factor: 9.941
Authors: Brandon J Peiffer; Le Qi; Ali R Ahmadi; Yuefan Wang; Zufeng Guo; Hanjing Peng; Zhaoli Sun; Jun O Liu Journal: Cell Chem Biol Date: 2019-02-28 Impact factor: 8.116
Authors: Oleh Akchurin; Angara Sureshbabu; Steve B Doty; Yuan-Shan Zhu; Edwin Patino; Susanna Cunningham-Rundles; Mary E Choi; Adele Boskey; Stefano Rivella Journal: Am J Physiol Renal Physiol Date: 2016-07-20
Authors: Adam E Gaweda; Yelena Z Ginzburg; Yossi Chait; Michael J Germain; George R Aronoff; Eliezer Rachmilewitz Journal: Nephrol Dial Transplant Date: 2014-05-12 Impact factor: 5.992